Lei Chen

Lei Chen

Auto-generated profile, based on publicly available information

Lei Chen

Merck & Co., Inc. Rahway New Jersey USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
MBMin-Hyun Baek
Min-Hyun Baek
LCLei Chen
Lei Chen
CTCumhur Tekin
Cumhur Tekin
RCRazvan Cristescu
Razvan Cristescu
XJXiao Yang Jin
Xiao Yang Jin
JPJeong-Yeol Park
Jeong-Yeol Park
Baek MH, et al. J Gynecol Oncol. 2024 May;35:e105. https://doi.org/10.3802/jgo.2024.35.e105

19 August 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
LSLe Su
Le Su
LCLei Chen
Lei Chen
SBSeema Betigeri
Seema Betigeri
NDNancy Dreyer
Nancy Dreyer
HGHelga Gardarsdottir
Helga Gardarsdottir
MBMehmet Burcu
Mehmet Burcu
Clinical trials with pragmatic elements can capture diverse patient populations, enable efficient follow‐up, and reflect routine clinical practices; yet there is limited understanding of their design features, characteristics, and use of real‐world data (RWD). Based on a targeted search of PubMed/EMBASE (Jan‐2016 to Jul‐2024), a review was conducted to characterize clinical trial use cases with pragmatic elements during the design and conduct of trials, as well as clinical trials that utilized RWD for long‐term follow‐up in the extension phase of the original (“parent”) trial. A total of 27 use cases were characterized. There were 22 use cases with pragmatic elements, and nearly all employed randomization ( n = 21, 95.5%), open‐label design ( n = 20, 90.9%), with usual/standard of care ( n = 13, 59.1%) as comparators. Most generated evidence on both effectiveness and safety ( n = 18, 81.8%), primarily in diabetes and cardiovascular disease areas ( n = 14, 63.6%). The most common pragmatic elements were broad eligibility criteria, flexible treatment management, minimal or no follow‐up, and streamlined endpoint collection. RWD (including electronic health records, claims, registries) was utilized in half of the use cases ( n = 4 to enrich trial data with additional information abstracted from RWD; n = 7 to embed trials within routine healthcare databases/systems). In addition, 5 use cases were identified that utilized RWD in the extension phase of the original “parent” trials (4 utilizing RWD for long‐term follow‐up purposes, and one utilizing RWD to construct external controls for clinical trial infrastructure‐based extension study). This review underscores the emerging role of pragmatic elements in enhancing trial efficiency, generalizability, and evidence generation on long‐term outcomes.

12 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LCLei Chen
Lei Chen
LHLisa Herms
Lisa Herms
JMJohn Murphy
John Murphy
GPGregory Patton
Gregory Patton
AGAudrey P. Garrett
Audrey P. Garrett
RARebecca C. Arend
Rebecca C. Arend
ObjectiveThis study aimed to evaluate patient characteristics, treatment patterns, and the correlation between real-world progression-free survival (rwPFS) and overall survival (rwOS) during first-line treatment in patients who have advanced epithelial ovarian cancer (EOC) with wild-type BRCA (wtBRCA) tumors treated in the US community oncology setting.MethodsThis was a retrospective observational cohort study of adult patients who underwent primary or interval debulking surgery for Stage III/IV wtBRCA EOC and initiated first-line platinum-based therapy (PBT) between 01/01/2017 and 04/30/2023 (index) using electronic health record (EHR) data from The US Oncology Network and non-Network practices, with chart abstraction to capture additional unstructured data. A secondary cohort of patients with confirmed HRD-negative disease was included. rwPFS and rwOS were analyzed using Kaplan–Meier methods and Cox proportional hazards models. The relationship between rwPFS and rwOS was assessed with Kendall’s tau.ResultsMean age at index was 66.3 years and most patients (74.0%) were White. Bevacizumab use was limited, with 63.7% receiving no bevacizumab in first-line or maintenance settings. Carboplatin plus paclitaxel (with or without bevacizumab) was the primary first-line treatment (91.3%). Median rwOS was 47.1 months (95% confidence interval [CI]: 42.6, 53.4), and median rwPFS was 27.7 months (95% CI: 21.3, 31.3). rwPFS and rwOS were moderately correlated (Kendall’s τ=0.63).ConclusionsCurrent clinical outcomes from patient-level analyses suggest that rwPFS and OS are moderately correlated in first-line treatment and underscore the ongoing need for optimized therapeutic approaches and novel early endpoints in clinical trials for patients with wtBRCA and HRD-negative disease.

28 September 2026 in Cancer
Verified
Journal Article
Closed access
PDF file
LSLe Su
Le Su
MBMehmet Burcu
Mehmet Burcu
KPKayleen Ports
Kayleen Ports
VGVlad Gradinariu
Vlad Gradinariu
YIYahav Itzkovich
Yahav Itzkovich
LCLei Chen
Lei Chen